Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel.

CONCLUSIONS: Neoadjuvant CbD yields encouraging efficacy in TNBC. Patients achieving pCR or RCB I with this regimen demonstrate excellent 3-year RFS and OS without adjuvant anthracycline.
PMID: 30061361 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - July 30, 2018 Category: Cancer & Oncology Authors: Sharma P, López-Tarruella S, Garcia-Saenz JA, Khan QJ, Gomez H, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell AC, Del Monte-Millán M, Gonzalez-Rivera M, Massarrah T, Pelaez-Lorenzo B, Palomero MI, González Del Val R, Cortes J, Fuentes Rive Tags: Clin Cancer Res Source Type: research